



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |           |   |
|---|-----------|---|
| <b>(51) International Patent Classification 5 :</b><br><b>A61K 9/16, 9/50, C08G 63/48</b><br><b>C08K 9/10</b>   | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 92/21327</b><br><br><b>(43) International Publication Date:</b> 10 December 1992 (10.12.92)   |
| <b>(21) International Application Number:</b> PCT/US92/04265<br><b>(22) International Filing Date:</b> 20 May 1992 (20.05.92)<br><br><b>(30) Priority data:</b><br>91/06441 29 May 1991 (29.05.91) FR<br><br><b>(71) Applicant (for all designated States except US):</b> SEPRACOR, INC. [US/US]; 33 Locke Drive, Marlborough, MA 01752 (US).<br><br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only) :</b> BOSCHETTI, Egisto [FR/FR]; 9, allée du Bois-Gougenot, F-78190 Croissy-sur-Seine (FR). BROUARD, Michel [FR/FR]; 12, bis rue Faubert, F-95270 Belloy-en-France (FR). DROUET, Ludovic [FR/FR]; 14, avenue des Cottages, F-92340 Bourg-la-Reine (FR). GIROT, Pierre [FR/FR]; 7, rue du Terrage, F-75010 Paris (FR). LAURENT, Alexandre [FR/FR]; 3, parc de Lattre-de-Tassigny, F-92400 Courbevoie (FR). WASSER, Michel [FR/FR]; 175, rue Saint-Jacques, F-75005 Paris (FR). |           | <b>(74) Agent:</b> MISROCK, S., Leslie; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).<br><br><b>(81) Designated States:</b> AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KR, LK, LU (European patent), MC (European patent), MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL (European patent), NO, PL, RO, RU, SD, SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent), US.<br><br><b>Published</b><br><i>With international search report.</i> |
| <b>(54) Title:</b> MICROSPHERES USEFUL FOR THERAPEUTIC VASCULAR OCCLUSIONS AND INJECTABLE SOLUTIONS CONTAINING THE SAME<br><br><b>(57) Abstract</b><br><br>The present invention concerns the use of microspheres for therapeutic embolization consisting of a hydrophilic acrylic copolymer coated with a cell adhesion promoter.  |           |   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |                          |
|----|--------------------------|----|--|----|--------------------------|
| AT | Austria                  | FI | Finland                                  | MI | Mali                     |
| AU | Australia                | FR | France                                   | MN | Mongolia                 |
| BB | Barbados                 | GA | Gabon                                    | MR | Mauritania               |
| BE | Belgium                  | GB | United Kingdom                           | MW | Malawi                   |
| BF | Burkina Faso             | GN | Guinea                                   | NL | Netherlands              |
| BG | Bulgaria                 | GR | Greece                                   | NO | Norway                   |
| BJ | Benin                    | HU | Hungary                                  | PL | Poland                   |
| BR | Brazil                   | IE | Ireland                                  | RO | Romania                  |
| CA | Canada                   | IT | Italy                                    | RU | Russian Federation       |
| CF | Central African Republic | JP | Japan                                    | SD | Sudan                    |
| CG | Congo                    | KP | Democratic People's Republic<br>of Korea | SE | Sweden                   |
| CH | Switzerland              | KR | Republic of Korea                        | SN | Senegal                  |
| CI | Côte d'Ivoire            | LI | Liechtenstein                            | SU | Soviet Union             |
| CM | Cameroon                 | LK | Sri Lanka                                | TD | Chad                     |
| CS | Czechoslovakia           | LU | Luxembourg                               | TG | Togo                     |
| DE | Germany                  | MC | Monaco                                   | US | United States of America |
| DK | Denmark                  | MG | Madagascar                               |    |                          |
| ES | Spain                    |    |  |    |                          |

- 1 -

MICROSPHERES USEFUL FOR THERAPEUTIC  
VASCULAR OCCLUSIONS AND INJECTABLE  
SOLUTIONS CONTAINING THE SAME

5        This invention concerns the subject of materials for embolization. In particular, it concerns new calibrated and adhesive particles, especially suited to embolization.

10        Therapeutic vascular occlusions (embolizations) are techniques used to treat certain pathological conditions *in situ*. They are practiced generally by means of catheters making it possible, under imagery control, to position particulate occlusion agents (emboli) in the circulatory system. They can concern  
15        the vessels of various processes: tumors, vascular malformations, hemorrhagic processes, etc. Notably, in the case of tumors, vascular occlusion can suppress pain, limit blood loss on the surgical intervention to follow embolization or even bring on tumoral necrosis  
20        and avoid the operation. In the case of vascular malformations, it enables the blood flow to the "normal" tissues to be normalized, aids in surgery and limits the risk of hemorrhage. In hemorrhagic processes, vascular occlusion produces a reduction of  
25        flow, which promotes cicatrization of the arterial opening(s).

         Furthermore, depending on the pathological conditions treated, embolization can be carried out for temporary as well as permanent objectives.

30        Different types of emboli are known in the prior art. In particular, liquid agents (acrylic glues, gels, viscous suspensions, etc.) or particulate agents (miscellaneous polymers, dura mater, gelatin sponges, spheres, balloons, spirals, etc.) can be involved.  
35        The major disadvantages of the known liquid emboli

reside in their toxicity to the tissues, which can generate necrosis phenomena, and in the risk of sticking of the catheters.

The disadvantages of the solid emboli available  
5 are essentially due to their nonspherical and hard-to-calibrate shape, to their nonhydrophilic character, to their hardness or even to their very high cost.

The present invention makes it possible to remedy the above-mentioned disadvantages. The applicant has,  
10 in fact, uncovered particularly advantageous properties of certain spherical materials, making possible their very effective use as emboli. The invention also resides in new emboli obtained by modifications of those materials, with a view to their  
15 application in embolization.

One object of the invention resides more specifically in the use of microspheres consisting of an hydrophilic acrylic copolymer coated with a cell adhesion promoter.

20 In particular, the invention concerns the use of microspheres of diameter ranging between about 10 to about 2,000  $\mu\text{m}$ .

Surprisingly, the microspheres defined above present properties very advantageous for embolization.  
25 Notably, they are the only emboli combining properties of effectiveness, biocompatibility and stability.

More precisely, the microspheres used in the invention affords a 100% occlusion of the vascular lumen. Furthermore, they are easily calibrated, which  
30 makes possible a control of the distance of the occlusion. Finally, they are nonresorbable and nonbiodegradable, which allows for a durable occlusion.

On the other hand, these microspheres are  
35 nontoxic, biocompatible *in vitro* (with numerous cell

lines) as well as *in vivo* and adhesive to the vascular wall through the cell growth they promote.

These microspheres are also stable. Thus, they are both flexible and deformable, in order to pass  
5 into small catheters without undergoing alteration, but perfectly resistant to the pressures generated by the embolization operations. They are likewise thermally stable, in order to be sterilized or frozen, and stable in suspension, in order to be preserved in  
10 suspension and injected with different liquids.

Finally, their hydrophilic character enables them to be placed in suspension, notably, in the form of sterile and pyrogenic injectable solutions, without formation of aggregates nor adhesion to the walls of  
15 the catheters, syringes, needles and other materials used in embolization.

The hydrophilic acrylic copolymer preferably contains in copolymerized form about 25 to about 98% neutral hydrophilic acrylic monomer by weight, about 2  
20 to about 50% difunctional monomer by weight and about 0 to about 50% by weight of one or more monomers carrying a cationic charge.

The presence of a cationic charge on the surface of the microsphere makes it possible to initiate and  
25 improve cell adhesion.

By way of example, the copolymers described in French Patent 2,378,808 can be suitable in this invention in formation of the base copolymer.

As hydrophilic acrylic monomer, the acrylamide  
30 and its derivatives, the methacrylamide and its derivatives or the hydromethylmethacrylate can be more specifically cited.

As example of difunctional monomer, the N,N'-methylene-bis-acrylamide, N'N'-diallyltartradiamide or  
35 even the glyoxal-bis-acrylamide can be cited.

Finally, as monomer having a cationic charge, those carrying a tertiary or quaternary amine function are preferred, such as diethylaminoethyl acrylamide, methacrylamidopropyl trimethylammonium or even  
5 acrylamidoethyl triethylammonium.

In a particularly advantageous manner, a copolymer containing about 25 to about 98% methacrylamide by weight, about 2 to about 50% N,N-methylene-bis-acrylamide by weight is used.

10 Different types of cell adhesion promoters can be employed. In particular, the cell adhesion promoters can be of collagen, gelatin, glucosaminoglycans, fibronectins, lectins, polycations (polylysine) or any other natural or synthetic biological cell adhesion  
15 agent.

The cell adhesion promoter advantageously represents in the microsphere between about 1 and about 50% by volume of the hydrophilic acrylic copolymer.

20 In one particularly advantageous embodiment of the invention, it is possible to increase the stability of the microspheres in reticulating the adhesion agent. By way of example, in the case of gelatin, the reticulating agent can be chosen among  
25 the difunctional chemical agents reacting on the gelatin amines (glutaraldehyde, formaldehyde, glyoxal, and the like).

Furthermore, the applicant has also developed new microspheres derived from those previously described,  
30 making possible a much easier application in embolization. Notably, one of the disadvantages of the materials described in the prior art is the difficulty the user has in visualizing them before, during and after injection under the naked eye or  
35 under imagery.

This problem is solved by a variant of the invention, consisting of identifiable microspheres containing an hydrophilic acrylic copolymer coated with a cell adhesion promoter and a marker. That  
5 property of microspheres can be obtained by modification during their synthesis or after their synthesis.

During their synthesis, the modifications can be obtained by incorporation with the other comonomers of  
10 a functionalized monomer carrying an identifiable function making detection of the microsphere possible.

For that purpose, a more particular object of the invention resides in microspheres for embolization consisting of a copolymer containing, in copolymerized  
15 form, about 25 to about 98% neutral hydrophilic acrylic monomer by weight, about 2 to about 50% difunctional monomer by weight, 0 to 50% by weight of one or more monomers carrying a cationic charge, and about 1 to about 30% by weight of a functionalized  
20 monomer making possible the detection of the microsphere, coated with a cell adhesion promoter.

More preferentially, microspheres having a diameter ranging between about 10 and about 2,000  $\mu\text{m}$  are involved.

25 As neutral hydrophilic acrylic monomer, as difunctional monomer, as charged monomers and as cell adhesion agent, those previously defined can be used.

The functionalized monomer is generally obtained by chemical coupling of the monomer with a marker,  
30 which can be:

- a chemical dye, such as Cibacron Blue or Procion Red HE-3B, making possible a direct visualization of the microspheres [Boschette, J. *Biochem-Biophys. Meth.* 19: 21-36 (1989)]. One can  
35 mention as functionalized monomer usable for this type

of marking N-acryloyl hexamethylene Cibacron Blue or N-acryloyl hexamethylene Procion Red HE-3B,

- a magnetic resonance imaging agent (erbium, gadolinium, magnetite) or even

- 5       - a contrasting agent, such as barium or iodine salts. One can mention, by way of example, (acrylamino-e-propion-amido)-3-triiodo-2,4,6-benzoic acid, which can be prepared under the conditions described by Boschette et al. (*Bull. Soc. Chim.* 10 France, 1986 No. 4). In the case of barium or magnetite salts, they can be directly introduced in powdered form in the initial monomer solution.

As indicated above, it is also possible to mark the microsphere after their synthesis. This can be 15 done, for example, by grafting of fluorescent markers such as erythrosine or fluorescein or their derivatives (FITC, EITC, and the like).

Another object of the invention concerns injectable solutions containing microspheres, as 20 previously defined. It preferably involves injectable solutions containing microspheres distributed in approximately 200  $\mu$  caliber segments.

The applicant has, in fact, shown that, by using restricted caliber segments, the efficacy of occlusion 25 and its distal control were markedly improved. Such injectable solutions thus make it possible to improve the efficacy of occlusion and to adapt treatment to the diameter and nature of the vessel to be embolized and to the process involved.

30       The microspheres of the invention can be obtained by standard methods of polymerization described in the prior art (French Patent 2,378,808). In general, the polymerization of monomers in solution is carried out at a temperature ranging between about 0°C and about



100°C and between about 40°C and about 60°C, in the presence of a polymerization reaction initiator.

The polymerization initiator is advantageously chosen among the redox systems. Notably, it is  
5 possible to use combinations of an alkali metal persulfate with N,N,N',N'-tetramethylethylenediamine or with dimethylaminopropionitrile, organic peroxides such as benzoyl peroxide or even 2,2'-azo-bis-isobutyronitrile.

10 The quantity of initiator used is adapted by one skilled in the art to the quantity of monomers and the rate of polymerization sought.

Polymerization can be carried out in mass or in emulsion.

15 In the case of a mass polymerization, the aqueous solution containing the different dissolved constituents and the initiator undergoes a polymerization in a homogeneous medium. It makes it possible to access a lump of aqueous gel which can  
20 then be separated into microspheres, by passing, for example, through the mesh of a screen.

Emulsion polymerization is the preferred method of preparation, since it makes it possible to access directly microspheres of a desired size. It can be  
25 conducted as follows: the aqueous solution containing the different dissolved constituents (different monomers, cell adhesion agent) is mixed, stirring, with a liquid organic phase not miscible in water, possibly in the presence of an emulsifier. The rate  
30 of stirring is adjusted so as to obtain an aqueous phase emulsion in the organic phase forming drops of desired diameter. Polymerization is then started off by addition of the initiator. It is accompanied by an exothermic reactions and its development can then be

followed by measuring the temperature of the reaction medium.

It is possible to use as organic phase vegetable or mineral oils, certain petroleum distillation products, chlorinated hydrocarbons or a mixture of those different solutions. Furthermore, in case the polymerization initiator includes several components (redox system), it is possible to add one of them in the aqueous phase before emulsification.

The microspheres thus obtained can then be recovered by cooling, decanting and filtration. They are then separated by size category and washed to eliminate any trace of secondary product.

The polymerization stage can be followed by a stage of reticulation of the cell adhesion agent and possibly by a marking stage in the case of microspheres rendered identifiable by grafting after synthesis.

This invention will be more completely described by means of the following examples, which are to be considered illustrative and not limitative.

#### EXAMPLE 1

In a beaker containing 100 ml of demineralized water, 58 g of sodium chloride and 27 g of sodium acetate are dissolved. One adds 400 ml of glycerol and then the pH is adjusted between 5.9 and 6.1. Then 90 g of N-tris-hydroxy-methyl methylacrylamide, 35 mg of diethylaminoethylacryl-amide and 10 g of N,N-methylene-bis-acrylamide are added. One heats at 60-70°C and 100 ml of a hot 300 mg/ml gelatin solution is added. The total volume of the mixture is adjusted to 980 ml by addition of hot water and then 20 ml of a 70 mg/ml ammonium persulfate solution and 4 ml of N,N,N',N'-tetramethylethylenediamine are added.

This solution is poured into paraffin oil at 50-70°C stirring. After a few minutes, the polymerization reaction of acrylic monomers is manifested by an increase of temperature. The  
5 microspheres are then recovered by decanting, washed carefully, screened and sterilized in an autoclave in a buffered medium.

Those microspheres, after screen calibration, possess the characteristics desired for embolization,  
10 including a marked cationic charge and an effective adhesion agent (gelatin or denatured collagen).

#### EXAMPLE 2

The procedure of Example 1 is followed, using  
15 triethylaminoethyl acrylamide instead of diethylaminoethyl acrylamide.

After recovery of the spheres, the gelatin is reticulated by means of a 25% glutaraldehyde solution (100 ml of all of the microspheres). The treatment is  
20 carried out stirring at 4°C overnight. It is followed by a washing with demineralized water.

#### EXAMPLES 3 AND 4

The procedure of Examples 1 and 2 is followed,  
25 replacing 10 g of N-tris-hydroxymethyl methylacrylamide with 10 g of N-acryloyl hexamethylene Cibacron Blue.

The microspheres obtained possess an intense blue coloration due to the integration of the acrylic dye  
30 in the polymer lattice.

Those microspheres are advantageously usable in direct view of the user at the time of handling.

#### EXAMPLES 5 and 6

The procedure of Examples 1 and 2 is followed, replacing N-tris-hydroxymethyl methyacrylamide with 10 g of N-acryloyl hexamethylene Procion Red HE-3B.

The microspheres obtained possess an intense red coloration due to the integration of the acrylic dye in the polymer lattice.

Those microspheres are advantageously usable in direct view of the user at the time of handling.

#### 10 EXAMPLES 7 AND 8

One hundred milliliters of microspheres obtained according to Examples 1 and 2 are washed with a 0.1 M borate buffer of pH 8 and then suspended in 50 ml of a 5 mg/ml erythrosine isothiocyanate solution. The suspension is then stirred for at least 15 hours, after which it is washed with a neutral buffer to a colorless supernatant.

Those red-colored microspheres are then calibrated and sterilized, and can be used in percutaneous embolization.

#### EXAMPLES 9 AND 10

The procedure of Examples 1 and 2 is followed, replacing 10 g of N-tris-hydroxymethyl methyacrylamide with 10 g of a monomer opaque to X-rays, (acrylamido-3-propionamido)-3-triiodo-2,4,6-benzoic acid.

The microspheres obtained possess the property of absorbing X-rays and are therefore of particular interest in their in vivo follow-up after embolization.

#### EXAMPLES 11 TO 14

The procedure of Examples 1 and 2 is followed, adding to the initial monomer solution 5 g of a radio-

opaque soluble linear polymer, acrylamino-3-triiodo-2,4,6-benzoic polyacid (Examples 11 and 12) or (acrylamino-3-propionamido)-3-triiodo-2,4,6-benzoic polyacid (Examples 13 and 14).

- 5        Those polymers, having a molecular weight exceeding 100,000 daltons, are imprisoned in the polymer lattice and, without disturbing the general properties of the microspheres for the applications claimed, make it possible to attain a radiopacity  
10        usable for the *in vivo* follow-up of embolization operations.

#### EXAMPLES 15 AND 16

- The procedure of Examples 1 and 2 is followed,  
15        adding to the initial monomer solution 200 g of barium sulfate power. The microspheres obtained are opaque to both visible light and X-rays.

#### EXAMPLES 17 AND 18

- 20        The procedure of Examples 1 and 2 is followed, adding 50 mg of magnetite ( $\text{Fe}_3\text{O}_4$ ) to the initial monomer solution.

- The microspheres obtained have the property of being detected in (Magnetic Resonance Imaging) MRI  
25        imagery.

#### EXAMPLE 19 - Comparative evaluation of two types of nonresorbable spheres

- The study consisted of injecting two types of  
30        calibrated microspheres, some prepared according to Example 2, the others of polystyrene (Biosilon Nunc Danemark), in pulmonary arterial vascularization of the rat and of observing on days 0, 8 and 30 the extent of the cell reaction and the remodeling  
35        modalities of the occluded vessels.

The study revealed four important facts:

- placement in suspension and vascular injection of the polystyrene spheres is difficult and clusters are formed at the segmental narrowing constituting the  
5 nozzle of the syringe, the base of the catheter and the possible changes of diameter of the catheters;
- the cell reaction is earlier, more intense and more durable with the spheres of Example 1 than with polystyrene. On the 8th day the thickness of the cell  
10 reaction covering the spheres of the invention is almost three times greater than that covering the polystyrene spheres ( $34\ \mu$  as compared to  $13\ \mu$ );
- there is no differences in kinetics in the vascular remodeling with either material;
- 15 - no phenomenon suggesting the toxicity of either material was observed.

In conclusion, the microspheres of the invention are more manageable and more effective as adhesive agent.

20

Example 20 - Clinical evaluation in 89 patients

One hundred procedures were carried out on various processes: 19 tumors, 75 arteriovenous malformations (12 facial AVM's, 40 medullary AVM's, 23  
25 cerebral AVM's) and 6 miscellaneous (including hemorrhages).

The spheres used were spheres prepared according to Example 1, calibrated so as to obtain the following segments (in  $\mu\text{m}$ ): 200-400, 400-600, 600-800, 800-1000  
30 and 1000-1200, in suspension in ready-to-use bottles.

At the conclusion of this study, several remarks can be made:

1. The injection of these spheres is extremely simple and easier than with all of the other existing  
35 particles. At no time did any phenomenon like

blocking of the systems necessary for injection (syringe, nozzle, base, connections, catheter, etc.) occur. Out of the 100 procedures, no accident occurred which might have been related to the equipment, its nature or shape. The follow-up of injection of the microspheres under radioscopy was easily secured by the addition of contrast products to the solution containing the microspheres in the injection syringe. No phenomenon of incompatibility between the microspheres and the different commercial vascular contrast products was observed.

2. In the case of tumors, devascularization could always be perfectly controlled with the two parameters of quantity of spheres and their diameter. Distribution of the spheres around fixed in narrow segments makes possible a better distal control of occlusion and command of the consequences of that occlusion: ischemia, necrosis, edema, etc. This is very important, particularly in conducting the embolization of certain tumors, like intracranial meningiomas, the tumoral necrosis of which can be accompanied by a severe edematous attack, compressing the healthy brain. The clinical course of 19 cases of tumors made it possible to uncover a new strategy of treatment of some of the tumors, consisting of embolizing in several stages with growing calibers in order to devascularize the tumor preoperatively.

3. In arteriovenous malformations the size required for the particles varied according to the process with, on first approach, the following tendencies:

- facial AVM: 300, 500  $\mu$
- medullary AVM: 700, 900  $\mu$
- cerebral AVM: 900 to 1500  $\mu$

4. Study of the correlation between angiographic devascularization and the histological data for two types of dispersion of microspheres in 16 embolized tumors, 8 with spheres distributed in broad  
5 segments ( $500 \pm 300 \mu$ ) and 8 in narrow segments ( $200 \pm 50 \mu$ ,  $400 \pm 50 \mu$ ,  $600 \pm 100 \mu$ ,  $800 \pm 100 \mu$ ) revealed that the extent of necrosis and the number of intratumoral spheres are significantly greater in the  
10 segments than in the one treated with broad segments.

In conclusion: the microspheres of the invention are easy to use and effective for all processes and the tissue effects of occlusion are controllable when the size peaks are close together.

15

#### Example 21

Comparative study of the durability of occlusion in medullary arteriovenous malformations treated with commercial nonspherical particles and microspheres  
20 prepared according to Example 1.

There were 84 afferent arteries of angiomas embolized: 48 with a nonspherical material and 26 with the microspheres.

The results of the study are:

25 - total or almost total occlusion of the malformation by the microspheres was obtained in 25% of the cases, and an 80% closure was obtained in 50% of the cases. By comparison, 100% occlusion of the malformation was accomplished in only 5.4% of the  
30 cases with nonspherical occlusion agents;

- the course of the occlusion differs according to whether or not the occluding agent is spherical, since the rate of reopening in 9 months is 80% with nonspherical particles and 40% with the microspheres.

35



WHAT IS CLAIMED IS:

1. A microsphere useful for embolization which comprises a hydrophilic acrylic copolymer coated with a cell adhesion promoter and a marking agent.
- 5 2. A microsphere for embolization according to claim 1, which comprises a copolymer containing, in copolymerized form, about 25 to about 98% neutral hydrophilic acrylic monomer by weight, about 2 to about 50% difunctional monomer by weight, about 0 to  
10 about 50% by weight of one or more monomers having a cationic charge, and about 1 to about 30% by weight of a functionalized monomer making possible the detection of the microsphere, coated with a cell adhesion promoter.
- 15 3. A microsphere according to claim 2, characterized in that the functionalized monomer comprises a monomer covalently linked to a marking agent selected from the group consisting of dyes, imaging agents and contrasting agents.
- 20 4. A microsphere according to claim 3, characterized in that the functionalized monomer is selected from the group consisting of N-acryloyl hexamethylene Cibacron Blue, N-acryloyl hexamethylene Procion Red HE-3B, (acrylamido-3-propionamido)-3-  
25 triiodo-2,4,6-benzoic acid, possibly in polymerized form, and acryl-amido-3-triiodo-2,4,6-benzoic polyacid.
5. A microsphere according to claim 3, characterized in that the marking agent is directly  
30 introduced in powdered form in the initial monomer solution.
6. A microsphere according to claims 1, 2, 3, 4, or 5, having a diameter ranging between about 10 to about 2,000  $\mu\text{m}$ .

7. An injectable solution for embolization, comprising a microsphere according to claims 1, 2, 3, 4, 5 or 6.

8. An injectable solution according to claim 7,  
5 which comprises microspheres in approximately 100  $\mu\text{m}$  caliber segments.

9. A method for the therapeutic embolization of microspheres which comprises administering to a mammal a microsphere according to claim 1.

10 10. The method according to claim 9 which comprises microspheres having a diameter ranging between about 10 and about 2,000  $\mu\text{m}$ .

11. The method according to claim 9, characterized in that the acrylic copolymer comprises,  
15 in copolymerized form, about 25 to about 98% neutral hydrophilic acrylic monomer by weight, about 2 to about 50% difunctional monomer by weight, and about 0 to about 50% by weight of one or more monomers carrying a cationic charge.

20 12. The method according to claim 11, characterized in that the neutral hydrophilic acrylic monomer is selected from the group consisting of acrylamides, methacrylamides and hydroxymethylmethacrylate.

25 13. The method according to claim 11, characterized in that the difunctional monomer is selected from the group consisting of N,N'-methylene-bis-acrylamide, N'N'-diallyltartradiamide and glyoxal-bis-acrylamide.

30 14. The method according to claim 11, characterized in that the monomer having a cationic charge is a monomer having a tertiary and/or quaternary amine function.

15. The method according to claim 9,  
35 characterized in that the cell adhesion promoter is

selected from the group consisting of collagen, gelatin, glucosaminoglycans, fibronectin, lectins, polycations and any other natural or synthetic biological cell adhesion agent.

- 5        16. The method according to claim 15, characterized in that the cell adhesion promoter represents about 1 to about 50% by volume of the acrylic copolymer.

10

15

20

25

30

35

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/04265

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) :A61K 9/16,9/50; C08G 63/48; C08K 9/10

US CL :523/200; 525/54.1; 424/490,497

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. :

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

USPTO APS 1) (embolise? or embolize?)

2) L1 and ? acryl?

3) L2 and (514\*?/CCLS or 525\*?/CCLS or 424\*?/CCLS)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| A         | US, A, 3,797,485 (URQUHART) 19 March 1974, See the entire document.                | 1-6,9-16              |
| A         | US, A, 4,536,387 (SAKAMOTO) 20 August 1985, See the entire document.               | 1-6,9-16              |
| A         | US, A, 4,801,458 (HIDAKA) 31 January 1989, See the entire document.                | 1-6,9-16              |
| A         | US, A, 4,990,340 (HIDAKA) 05 February 1991, See the entire document.               | 1-6,9-16              |

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

|   |    |  |
|---|----|--|
| * Special categories of cited documents:  | T  | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| *A* document defining the general state of the art which is not considered to be part of particular relevance   | X* | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| *E* earlier document published on or after the international filing date  | Y* | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | G* | document member of the same patent family  |
| *O* document referring to an oral disclosure, use, exhibition or other means  |    |  |
| *P* document published prior to the international filing date but later than the priority date claimed  |    |  |

Date of the actual completion of the international search

27 JULY 1992

Date of mailing of the international search report

16 SEP 1992

Name and mailing address of the ISA/ u.s.  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

*Nathan M. Nutter*  
NATHAN M. NUTTER NGOC-HO  
INTERNATIONAL DIVISION  
Telephone No. (703) 308-2351